Loading
A phase 1/2 trial of Cetuximab, CAPOX, FLOT in colorectal cancer, run by Haisco Pharmaceutical Group Co., Ltd., now recruiting.
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT07790510 by Haisco Pharmaceutical Group Co., Ltd., with 180 participants planned, started 2026-08-12 and due to reach its primary completion in 2029-09-30. Interventions recorded: HSK42360-Na Tablets, Cetuximab (EGFR inhibitor), mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU), FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU). Conditions listed: Metastatic Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Cetuximab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Monoclonal antibodies, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Cetuximab.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Monoclonal antibodies, Colorectal cancer.